NCT07481396 Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
| NCT ID | NCT07481396 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chungnam National University Hospital |
| Condition | Cardiac Arrest (CA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-12-01 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques. The main question this study aims to answer is: Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest? To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.
Eligibility Criteria
Inclusion Criteria: * Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment. * Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of: * Uncontrolled diabetes.Coagulation disorders. * Thrombocytopenia (platelet count $\< 100,000). * A history of cirrhosis diagnosis. * Current receipt of low molecular weight heparin. * Current use of platelet inhibitors. * A history of posterior spinal fusion that may interfere with catheter insertion. * Local skin infection or rash at the puncture site. * Signs of systemic infection or sepsis. * A history of lumbar puncture within the past 6 hours. Exclusion Criteria: * Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery. * Patients who underwent extracorporeal membrane oxygenation (ECMO). * Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest. * Patients with a history of acute or chronic brain disease.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07481396 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiac Arrest (CA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07481396 currently recruiting?
Yes, NCT07481396 is actively recruiting participants. Contact the research team at rosc@cnu.ac.kr for enrollment information.
Where is the NCT07481396 trial being conducted?
This trial is being conducted at Daejeon, South Korea.
Who is sponsoring the NCT07481396 clinical trial?
NCT07481396 is sponsored by Chungnam National University Hospital. The trial plans to enroll 60 participants.